Shield Therapeutics(DE:1JS)
€0.03+0.00 (+0.00%)
DE:1JS
Shield Therapeutics financials statements
€0.03
At close:+0.00 (+0.00%)
Shield Therapeutics (1JS) Ratios
2 Followers
Shield Therapeutics Ratios
DE:1JS's free cash flow for Q2 2026 was £712.11K. For the 2026 fiscal year, DE:1JS's free cash flow was decreased by £-27.77K and operating cash flow was £739.89K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.90 | 1.16 | 2.90 | 0.95 | 5.11 |
| Quick Ratio | 0.72 | 0.99 | 2.60 | 0.81 | 4.62 |
| Cash Ratio | 0.23 | 0.22 | 1.29 | 0.27 | 3.58 |
| Solvency Ratio | -0.21 | -0.43 | -1.22 | -2.26 | -5.07 |
| Operating Cash Flow Ratio | -0.18 | -0.27 | -3.45 | -1.72 | -4.95 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -56.01 | -221.16 | -205.14 | -107.29 |
| Net Current Asset Value | £ -35.09M | £ -20.84M | £ 4.78M | £ -6.55M | £ 13.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.46 | 0.46 | 0.42 | 0.28 | 0.00 |
| Debt-to-Equity Ratio | -2.00 | -20.02 | 1.73 | 1.12 | 0.00 |
| Debt-to-Capital Ratio | 2.00 | 1.05 | 0.63 | 0.53 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 2.00 | 1.05 | 0.63 | 0.53 | 0.00 |
| Financial Leverage Ratio | -4.33 | -43.64 | 4.14 | 4.07 | 1.09 |
| Debt Service Coverage Ratio | -1.28 | -5.31 | -31.60 | -110.06 | -106.48 |
| Interest Coverage Ratio | -1.36 | -5.92 | -38.22 | -79.09 | -2550.63 |
| Debt to Market Cap | 0.35 | 1.08 | 0.41 | 0.37 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.03 | 0.03 | 0.03 | 0.00 |
| Net Debt to EBITDA | -2.02 | -0.93 | -0.21 | -0.07 | 0.68 |
| Profitability Margins | |||||
| Gross Profit Margin | 44.11% | 41.97% | 30.78% | 36.32% | 35.48% |
| EBIT Margin | -20.29% | -70.25% | -239.66% | -889.98% | -1310.01% |
| EBITDA Margin | -18.05% | -65.82% | -231.47% | -837.73% | -1164.71% |
| Operating Profit Margin | -20.29% | -72.59% | -239.44% | -479.92% | -1343.32% |
| Pretax Profit Margin | -34.49% | -82.52% | -247.42% | -728.90% | -1310.53% |
| Net Profit Margin | -35.52% | -84.47% | -254.44% | -735.48% | -1272.94% |
| Continuous Operations Profit Margin | -35.52% | -84.47% | -254.44% | -735.05% | -1295.46% |
| Net Income Per EBT | 103.00% | 102.36% | 102.84% | 100.90% | 97.13% |
| EBT Per EBIT | 169.95% | 113.68% | 103.33% | 151.88% | 97.56% |
| Return on Assets (ROA) | -27.63% | -46.35% | -68.22% | -183.22% | -43.54% |
| Return on Equity (ROE) | 119.51% | 2022.89% | -282.32% | -745.24% | -47.52% |
| Return on Capital Employed (ROCE) | -68.36% | -92.11% | -82.40% | -230.79% | -49.73% |
| Return on Invested Capital (ROIC) | -68.36% | -90.82% | -81.58% | -226.90% | -48.72% |
| Return on Tangible Assets | -38.89% | -67.77% | -104.25% | -393.00% | -110.10% |
| Earnings Yield | -20.76% | -108.89% | -68.77% | -246.01% | -21.26% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.08 | 1.25 | 1.23 | 1.47 | 0.86 |
| Payables Turnover | 0.76 | 0.79 | 2.24 | 1.42 | 0.23 |
| Inventory Turnover | 3.08 | 3.23 | 2.83 | 1.70 | 0.60 |
| Fixed Asset Turnover | 448.90 | 84.56 | 19.44 | 27.91 | 5.00 |
| Asset Turnover | 0.78 | 0.55 | 0.27 | 0.25 | 0.03 |
| Working Capital Turnover Ratio | 276.68 | 1.85 | 1.31 | 0.82 | 0.18 |
| Cash Conversion Cycle | -187.81 | -57.26 | 261.59 | 208.06 | -529.30 |
| Days of Sales Outstanding | 175.43 | 292.25 | 295.68 | 249.14 | 426.03 |
| Days of Inventory Outstanding | 118.63 | 112.89 | 129.07 | 215.31 | 608.95 |
| Days of Payables Outstanding | 481.87 | 462.40 | 163.16 | 256.39 | 1564.29 |
| Operating Cycle | 294.06 | 405.14 | 424.75 | 464.44 | 1034.99 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.05 | -0.08 | -0.08 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.06 | -0.09 | -0.09 |
| Dividend Paid and CapEx Coverage Ratio | -359.45 | -255.78 | -12.59 | -9.63 | -8.11 |
| Capital Expenditure Coverage Ratio | -359.45 | -255.78 | -12.59 | -9.63 | -8.11 |
| Operating Cash Flow Coverage Ratio | -0.29 | -0.33 | -1.82 | -2.99 | -107.29 |
| Operating Cash Flow to Sales Ratio | -0.17 | -0.28 | -2.84 | -3.32 | -11.02 |
| Free Cash Flow Yield | -10.17% | -36.01% | -82.78% | -122.52% | -20.67% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.80 | -0.92 | -1.45 | -0.41 | -4.70 |
| Price-to-Sales (P/S) Ratio | 1.71 | 0.78 | 3.70 | 2.99 | 59.88 |
| Price-to-Book (P/B) Ratio | -5.76 | -18.58 | 4.11 | 3.03 | 2.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.83 | -2.78 | -1.21 | -0.82 | -4.84 |
| Price-to-Operating Cash Flow Ratio | -9.86 | -2.79 | -1.30 | -0.90 | -5.43 |
| Price-to-Earnings Growth (PEG) Ratio | 0.16 | 0.02 | 0.02 | -0.01 | -0.01 |
| Enterprise Value Multiple | -11.50 | -2.11 | -1.81 | -0.43 | -4.47 |
| Enterprise Value | 105.33M | 43.77M | 54.88M | 19.72M | 79.00M |
| EV to EBITDA | -11.50 | -2.11 | -1.81 | -0.43 | -4.47 |
| EV to Sales | 2.08 | 1.39 | 4.19 | 3.59 | 52.01 |
| EV to Free Cash Flow | -11.93 | -4.97 | -1.37 | -0.98 | -4.20 |
| EV to Operating Cash Flow | -11.96 | -4.99 | -1.48 | -1.08 | -4.72 |
| Tangible Book Value Per Share | -0.04 | -0.02 | 0.01 | -0.03 | 0.07 |
| Shareholders’ Equity Per Share | -0.02 | -0.00 | 0.02 | 0.02 | 0.20 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | -0.02 | -0.03 | -0.01 | 0.01 |
| Revenue Per Share | 0.06 | 0.03 | 0.02 | 0.02 | 0.01 |
| Net Income Per Share | -0.02 | -0.03 | -0.05 | -0.17 | -0.09 |
| Tax Burden | 1.03 | 1.02 | 1.03 | 1.01 | 0.97 |
| Interest Burden | 1.70 | 1.17 | 1.03 | 0.82 | 1.00 |
| Research & Development to Revenue | 0.03 | 0.06 | 0.14 | 0.19 | 0.38 |
| SG&A to Revenue | 0.61 | 1.07 | 1.16 | 4.97 | 13.18 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.07 | 0.17 | 0.88 |
| Income Quality | 0.49 | 0.33 | 1.12 | 0.64 | 0.85 |
Currency in GBP
